| Literature DB >> 2079572 |
R Müller1, R Baumgarten, R Markus, M Schulz, H Wittenberg, B Hintsche-Kilger, J D Fengler, P Von Wussow, H Meisel, H Klein.
Abstract
A total of 58 patients with histologically confirmed chronic viral hepatitis B and presence of hepatitis B surface antigen and hepatitis B virus DNA (HBV DNA) in the serum were randomized in a prospectively controlled trial. Thirty patients were treated with 3 megaunits of recombinant interferon alfa-2b (INTRON A, R Schering-Plough, Essex Corporation) subcutaneously thrice weekly for 4 months. Twenty-eight controls received no treatment. The post-treatment follow-up period consisted of 6 months. Twenty-eight treated patients and 27 controls completed the protocol. One female patient of the treatment group showed a complete response, and eight other treated patients (32%) showed a partial response to therapy. Three patients in the control group (11%) lost hepatitis B e antigen and HBV DNA spontaneously. This finding is statistically significant (p less than 0.05). The elimination of hepatitis B virus markers from the serum was associated with a normalization of aminotransferase activities in the serum. Reactivation of hepatitis was not observed after seroconversion.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2079572 DOI： 10.1016/0168-8278(90)90181-p
Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083